메뉴 건너뛰기




Volumn 13, Issue 3, 2008, Pages 337-340

Hepatitis B antiviral resistance and vaccine escape: Two sides of the same coin

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INTERFERON; LAMIVUDINE; NEUTRALIZING ANTIBODY; PEGINTERFERON; TELBIVUDINE; EPITOPE; P PROTEIN, HEPATITIS B VIRUS; POL PROTEIN;

EID: 47249121336     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note
Times cited : (14)

References (38)
  • 1
    • 0036293243 scopus 로고    scopus 로고
    • Global control of hepatitis B virus infection
    • Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002; 2:395-403.
    • (2002) Lancet Infect Dis , vol.2 , pp. 395-403
    • Kao, J.H.1    Chen, D.S.2
  • 2
    • 0032801432 scopus 로고    scopus 로고
    • Impact of routine infant and adolescent hepatitis B vaccination in Tuscany, Central Italy
    • Bonanni P, Colombai R, Gasparini R, et al. Impact of routine infant and adolescent hepatitis B vaccination in Tuscany, Central Italy. Pediatr Infect Dis J 1999; 18:677-682.
    • (1999) Pediatr Infect Dis J , vol.18 , pp. 677-682
    • Bonanni, P.1    Colombai, R.2    Gasparini, R.3
  • 3
    • 0034048304 scopus 로고    scopus 로고
    • Elimination of new chronic hepatitis B virus infections: Results of the Alaska immunization program
    • Harpaz R, McMahon BJ, Margolis HS, et al. Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. J Infect Dis 2000; 181:413-418.
    • (2000) J Infect Dis , vol.181 , pp. 413-418
    • Harpaz, R.1    McMahon, B.J.2    Margolis, H.S.3
  • 4
    • 0035898929 scopus 로고    scopus 로고
    • The first five years of universal hepatitis B vaccination in South Africa: Evidence for elimination of HBsAg carriage in under 5-year-olds
    • Tsebe KV, Burnett RT, Hlungwani NP, Sibara MM, Venter PA, Mphahlele MJ. The first five years of universal hepatitis B vaccination in South Africa: evidence for elimination of HBsAg carriage in under 5-year-olds. Vaccine 2001; 19:3919-3926.
    • (2001) Vaccine , vol.19 , pp. 3919-3926
    • Tsebe, K.V.1    Burnett, R.T.2    Hlungwani, N.P.3    Sibara, M.M.4    Venter, P.A.5    Mphahlele, M.J.6
  • 5
    • 3142532627 scopus 로고    scopus 로고
    • Prevalence of HBsAg mutants and impact of hepatitis B infant immunisation in four Pacific Island countries
    • Basuni AA, Butterworth L, Cooksley G, Locarnini S, Carman WF. Prevalence of HBsAg mutants and impact of hepatitis B infant immunisation in four Pacific Island countries. Vaccine 2004; 22:2791-2799.
    • (2004) Vaccine , vol.22 , pp. 2791-2799
    • Basuni, A.A.1    Butterworth, L.2    Cooksley, G.3    Locarnini, S.4    Carman, W.F.5
  • 6
    • 0019985965 scopus 로고
    • Synthesis and assembly of hepatitis B virus surface antigen particles in yeast
    • Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982; 298:347-350.
    • (1982) Nature , vol.298 , pp. 347-350
    • Valenzuela, P.1    Medina, A.2    Rutter, W.J.3    Ammerer, G.4    Hall, B.D.5
  • 7
    • 0021337752 scopus 로고
    • Antigenic structure of hepatitis B surface antigen: Identification of the 'd' subtype determinant by chemical modification and use of monoclonal antibodies
    • Peterson DL, Paul DA, Lam J, Tribby I, Achord DT Antigenic structure of hepatitis B surface antigen: identification of the 'd' subtype determinant by chemical modification and use of monoclonal antibodies. J Immunol 1984; 132:920-927.
    • (1984) J Immunol , vol.132 , pp. 920-927
    • Peterson, D.L.1    Paul, D.A.2    Lam, J.3    Tribby, I.4    Achord, D.T.5
  • 9
    • 0023470784 scopus 로고
    • HBsAG positive reactivity in man not due to hepatitis B virus
    • Coursaget P, Yvonnet B, Bourdil C, et al. HBsAG positive reactivity in man not due to hepatitis B virus. Lancet 1987; 2:1354-1358.
    • (1987) Lancet , vol.2 , pp. 1354-1358
    • Coursaget, P.1    Yvonnet, B.2    Bourdil, C.3
  • 11
    • 0030625754 scopus 로고    scopus 로고
    • The clinical significance of surface antigen variants of hepatitis B virus
    • Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepatitis 1997; 4:11-20.
    • (1997) J Viral Hepatitis , vol.4 , pp. 11-20
    • Carman, W.F.1
  • 12
    • 0002047543 scopus 로고    scopus 로고
    • Surface variation of HBV: Scientific and medical relevance
    • Wallace WA, Carman WF. Surface variation of HBV: scientific and medical relevance. Viral Hepatitis Rev 1997; 3:5-16.
    • (1997) Viral Hepatitis Rev , vol.3 , pp. 5-16
    • Wallace, W.A.1    Carman, W.F.2
  • 13
    • 0029159858 scopus 로고
    • Molecular epidemiology of hepatitis B virus vaccine variants in Singapore
    • Oon CJ, Lim GK, Ye Z, et al. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 1995; 13:699-702.
    • (1995) Vaccine , vol.13 , pp. 699-702
    • Oon, C.J.1    Lim, G.K.2    Ye, Z.3
  • 14
    • 0032713817 scopus 로고    scopus 로고
    • Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan
    • Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 1999; 30:1312-1317.
    • (1999) Hepatology , vol.30 , pp. 1312-1317
    • Hsu, H.Y.1    Chang, M.H.2    Liaw, S.H.3    Ni, Y.H.4    Chen, H.L.5
  • 15
    • 0035003596 scopus 로고    scopus 로고
    • Variants within the 'a' determinant of HBs gene in children and adolescents with and without hepatitis B vaccination as part of Thailand's Expanded Program on Immunization (EPI)
    • Theamboonlers A, Chongsrisawat V, Jantaradsamee P, Poovorawan Y. Variants within the 'a' determinant of HBs gene in children and adolescents with and without hepatitis B vaccination as part of Thailand's Expanded Program on Immunization (EPI). Tohoku J Exp Med 2001; 193:197-205.
    • (2001) Tohoku J Exp Med , vol.193 , pp. 197-205
    • Theamboonlers, A.1    Chongsrisawat, V.2    Jantaradsamee, P.3    Poovorawan, Y.4
  • 16
    • 0035700331 scopus 로고    scopus 로고
    • Prevalence of vaccine-induced escape mutants of hepatitis B virus in the adult population in China: A prospective study in 176 restaurant employees
    • He C, Nomura F, Itoga S, Isobe K, Nakai T. Prevalence of vaccine-induced escape mutants of hepatitis B virus in the adult population in China: a prospective study in 176 restaurant employees. J. Gastroenterol Hepatol 2001; 16:1373-1377.
    • (2001) J. Gastroenterol Hepatol , vol.16 , pp. 1373-1377
    • He, C.1    Nomura, F.2    Itoga, S.3    Isobe, K.4    Nakai, T.5
  • 17
    • 0036038911 scopus 로고    scopus 로고
    • Restoration of replication phenotype of lamivudine resistant hepatitis B virus mutants by compensatory changes in the 'fingers' sub-domain of the viral polymerase selected as a consequence of mutations in the overlapping S gene
    • Torresi J, Earnest-Silveira L, Civitico G, et al. Restoration of replication phenotype of lamivudine resistant hepatitis B virus mutants by compensatory changes in the 'fingers' sub-domain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002; 299:88-99.
    • (2002) Virology , vol.299 , pp. 88-99
    • Torresi, J.1    Earnest-Silveira, L.2    Civitico, G.3
  • 18
    • 0036059889 scopus 로고    scopus 로고
    • Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy
    • Torresi J, Earnest-Silveira L, Deliyannis G, et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002; 293:305-313.
    • (2002) Virology , vol.293 , pp. 305-313
    • Torresi, J.1    Earnest-Silveira, L.2    Deliyannis, G.3
  • 19
    • 0034040297 scopus 로고    scopus 로고
    • Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy
    • Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000; 31:1318-1326.
    • (2000) Hepatology , vol.31 , pp. 1318-1326
    • Yeh, C.T.1    Chien, R.N.2    Chu, C.M.3    Liaw, Y.F.4
  • 20
    • 0033754947 scopus 로고    scopus 로고
    • Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy
    • Lok AS-F, Hussain M, Cursano C, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000; 32:1145-1153.
    • (2000) Hepatology , vol.32 , pp. 1145-1153
    • Lok, A.S.-F.1    Hussain, M.2    Cursano, C.3
  • 21
    • 0034048756 scopus 로고    scopus 로고
    • Predictions of the emergence of vaccine-resistant hepatitis B in the Gambia using a mathematical model
    • Wilson JN, Nokes DJ, Carman WF. Predictions of the emergence of vaccine-resistant hepatitis B in the Gambia using a mathematical model. Epidemiol Infect 2000; 124:295-307.
    • (2000) Epidemiol Infect , vol.124 , pp. 295-307
    • Wilson, J.N.1    Nokes, D.J.2    Carman, W.F.3
  • 22
    • 0142092372 scopus 로고    scopus 로고
    • The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro
    • Delaney WEt, Yang H, Westland CE, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003; 77:11833-11841.
    • (2003) J Virol , vol.77 , pp. 11833-11841
    • Delaney, W.E.1    Yang, H.2    Westland, C.E.3
  • 23
    • 0036161381 scopus 로고    scopus 로고
    • Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation
    • Bock TC, Tillmann HL, Torresi J, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122:264-273.
    • (2002) Gastroenterology , vol.122 , pp. 264-273
    • Bock, T.C.1    Tillmann, H.L.2    Torresi, J.3
  • 24
    • 33751514752 scopus 로고    scopus 로고
    • Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma
    • Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46:45-52.
    • (2007) J Hepatol , vol.46 , pp. 45-52
    • Lin, S.M.1    Yu, M.L.2    Lee, C.M.3
  • 25
    • 13444309139 scopus 로고    scopus 로고
    • A randomized, controlled trial of combination therapy for chronic hepatitis B: Comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone
    • Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142:240-250.
    • (2005) Ann Intern Med , vol.142 , pp. 240-250
    • Chan, H.L.1    Leung, N.W.2    Hui, A.Y.3
  • 26
    • 32944458551 scopus 로고    scopus 로고
    • Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs
    • author reply 1459-1460
    • Janssen HL, Lau GK. Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs. Hepatology 2005; 42:1459; author reply 1459-1460.
    • (2005) Hepatology , vol.42 , pp. 1459
    • Janssen, H.L.1    Lau, G.K.2
  • 27
  • 29
    • 33644818518 scopus 로고    scopus 로고
    • A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
    • Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010.
    • (2006) N Engl J Med , vol.354 , pp. 1001-1010
    • Chang, T.T.1    Gish, R.G.2    de Man, R.3
  • 30
    • 33644822860 scopus 로고    scopus 로고
    • Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B
    • Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354:1011-1020.
    • (2006) N Engl J Med , vol.354 , pp. 1011-1020
    • Lai, C.L.1    Shouval, D.2    Lok, A.S.3
  • 31
    • 19944428132 scopus 로고    scopus 로고
    • Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial
    • Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365:123-129.
    • (2005) Lancet , vol.365 , pp. 123-129
    • Janssen, H.L.1    van Zonneveld, M.2    Senturk, H.3
  • 32
    • 21244447705 scopus 로고    scopus 로고
    • Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
    • Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682-2695.
    • (2005) N Engl J Med , vol.352 , pp. 2682-2695
    • Lau, G.K.1    Piratvisuth, T.2    Luo, K.X.3
  • 33
    • 4544239807 scopus 로고    scopus 로고
    • Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
    • Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206-1217.
    • (2004) N Engl J Med , vol.351 , pp. 1206-1217
    • Marcellin, P.1    Lau, G.K.2    Bonino, F.3
  • 34
    • 33748929265 scopus 로고    scopus 로고
    • Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B
    • Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44:675-684.
    • (2006) Hepatology , vol.44 , pp. 675-684
    • Wursthorn, K.1    Lutgehetmann, M.2    Dandri, M.3
  • 35
    • 42149135950 scopus 로고    scopus 로고
    • Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication
    • Lutgehetmann M, Volzt T, Quaas A et al. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. Antivir Ther 2008; 13:57-66.
    • (2008) Antivir Ther , vol.13 , pp. 57-66
    • Lutgehetmann, M.1    Volzt, T.2    Quaas, A.3
  • 36
    • 34047130122 scopus 로고    scopus 로고
    • Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B
    • Lampertico P, Marzano A, Levrero M, et al. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. Hepatology 2006; 44 Suppl 1:693A.
    • (2006) Hepatology , vol.44 , Issue.SUPPL. 1
    • Lampertico, P.1    Marzano, A.2    Levrero, M.3
  • 37
    • 35648982926 scopus 로고    scopus 로고
    • Low resistance to adefovir combined with lamivudine: A 3-year study of 145 lamivudine-resistant hepatitis B patients
    • Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133:1445-1451.
    • (2007) Gastroenterology , vol.133 , pp. 1445-1451
    • Lampertico, P.1    Viganò, M.2    Manenti, E.3    Iavarone, M.4    Sablon, E.5    Colombo, M.6
  • 38
    • 34247475757 scopus 로고    scopus 로고
    • Combination of adefovir dipivoxil with lamivudine vs. adefovir alone in lamivudine-resistant HBeAg-negative chronic hepatitis B patients
    • Rapti IN, Dimou E, Mitsoula P, Hadziyannis SJ. Combination of adefovir dipivoxil with lamivudine vs. adefovir alone in lamivudine-resistant HBeAg-negative chronic hepatitis B patients. Hepatology 2006; 44 Suppl 1:558A.
    • (2006) Hepatology , vol.44 , Issue.SUPPL. 1
    • Rapti, I.N.1    Dimou, E.2    Mitsoula, P.3    Hadziyannis, S.J.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.